Getinge, the Swedish medical technology giant, has officially announced the appointment of Stacy Beske as the new President of its Acute Care Therapies business area, a move seen by industry analysts as a strategic effort to stabilize and revitalize its most significant revenue-generating division. Beske, a seasoned executive who currently serves as the Senior Vice President and Business Unit Leader for Image Guided Therapy Devices at Philips, will formally assume her new responsibilities on December 1, 2024. Her transition to Getinge comes at a pivotal moment for the company as it grapples with rigorous regulatory scrutiny from the U.S. Food and Drug Administration (FDA) and seeks to maintain its market-leading position in the high-stakes field of life-support technologies.
The leadership change follows the departure of Elin Frostehav, who has served as the head of the Acute Care Therapies unit and is leaving Getinge to become the Chief Executive Officer of Vitrolife Group, a medtech firm specializing in reproductive health. To ensure organizational stability during this period of transition, Frostehav will remain with Getinge for an interim period, facilitating a comprehensive handover of operations to Beske. This executive shuffle highlights the competitive nature of the MedTech talent landscape, where leaders with clinical backgrounds and operational expertise are in high demand to navigate increasingly complex global healthcare markets.
A Profile in Clinical and Executive Excellence
Stacy Beske brings a formidable blend of academic rigor and industrial experience to Getinge. Holding a Ph.D. in cardiovascular physiology, her career has been defined by a deep understanding of the clinical applications of medical devices. Prior to her tenure at Philips, Beske spent more than 18 years at Medtronic, one of the world’s largest medical device companies. During her nearly two decades at Medtronic, she held various leadership roles that spanned clinical research, product development, and business strategy.
This background is particularly relevant for Getinge’s Acute Care Therapies unit, which focuses on life-saving technologies used in intensive care units and operating rooms. Getinge CEO Mattias Perjo emphasized that Beske’s "strong track record of leading complex businesses and transformations" was a primary factor in her selection. Perjo noted that her history of building high-performing teams would be instrumental as the company works to strengthen the unit’s operational framework and address lingering quality concerns. Beske’s appointment suggests a shift toward leadership that prioritizes clinical integrity and regulatory compliance as foundational elements of business growth.
The Financial Pillar of Getinge: Acute Care Therapies
The Acute Care Therapies division is the cornerstone of Getinge’s financial structure. According to the company’s financial disclosures for the first nine months of 2024, the unit accounted for more than 50% of the company’s total net sales. The division’s portfolio includes critical technologies such as the Cardiohelp II, a portable extracorporeal life support (ECLS) system, and the Vasoview Hemopro 2, an endoscopic vessel harvesting system used in coronary artery bypass grafting.
Despite its massive contribution to the bottom line, the unit has faced performance challenges relative to Getinge’s other divisions, which include Life Sciences and Surgical Workflows. While those segments have shown robust growth in order intake and sales, the Acute Care Therapies unit has experienced a slower growth trajectory. In recent earnings calls, Getinge leadership acknowledged that while demand for life-support systems remains high globally, internal challenges—ranging from supply chain disruptions to quality management—have hampered the unit’s ability to fully capitalize on market opportunities.
Navigating Regulatory and Quality Hurdles
The most pressing challenge awaiting Beske is the resolution of ongoing quality issues that have attracted the attention of international regulators, most notably the U.S. FDA. In early 2024, the FDA issued a significant safety communication regarding Getinge’s Cardiosave and Cardiohelp devices. These devices, which include intra-aortic balloon pumps (IABP) and oxygenators used in extracorporeal membrane oxygenation (ECMO), are vital for patients suffering from cardiogenic shock or acute respiratory distress syndrome (ARDS).
The FDA’s advisory went as far as to suggest that healthcare providers should consider transitioning away from these Getinge products if alternative options were available, citing a series of recalls and technical malfunctions that could potentially compromise patient safety. For a company like Getinge, which prides itself on being a "quality-first" organization, these developments have been both a reputational and financial blow.
CEO Mattias Perjo has been vocal about the company’s commitment to remediating these issues. In a recent earnings call, Perjo stated that the company is "addressing the remaining challenges when it comes to quality work in acute care therapies." Beske’s arrival is expected to accelerate these efforts. Her experience at Medtronic and Philips—both companies that operate under intense regulatory oversight—provides her with the necessary perspective to implement the rigorous quality management systems required to regain the full confidence of the FDA and the global medical community.
Chronology of the Transition and Strategic Context
The timeline for Beske’s integration into Getinge is structured to minimize disruption:
- October 2024: Getinge announces the appointment of Stacy Beske and the departure of Elin Frostehav.
- November 2024: Transition phase where Frostehav and Beske engage in high-level strategic handovers.
- December 1, 2024: Stacy Beske officially takes the helm as President of Acute Care Therapies.
- Q1 2025: Beske is expected to present an updated operational roadmap focusing on quality remediation and market expansion.
The broader context of this move is the ongoing evolution of the global MedTech industry. Following the COVID-19 pandemic, there has been a surge in demand for respiratory and circulatory support systems. However, this demand has been met with increased scrutiny regarding device reliability. Getinge’s competitors, such as LivaNova and Terumo, have been vying for market share in the ECMO and IABP spaces, making it imperative for Getinge to resolve its quality issues swiftly to prevent further erosion of its market dominance.
Technical Scope: Cardiohelp and Vasoview
To understand the weight of Beske’s new role, one must look at the technologies under her purview. The Cardiohelp system is often described as the world’s smallest portable heart-lung machine. It is used to replace the function of the heart and lungs in patients whose organs are failing. The ability to provide this level of support in a portable format is revolutionary for patient transport and emergency interventions.
Similarly, the Vasoview Hemopro 2 system is a leader in endoscopic vessel harvesting (EVH). By allowing surgeons to harvest veins for bypass surgery through small incisions rather than long, invasive cuts, the technology significantly reduces patient recovery time and the risk of infection. Beske’s clinical background in cardiovascular physiology will allow her to engage directly with the surgeons and perfusionists who use these tools, ensuring that Getinge’s research and development efforts remain aligned with the needs of the modern operating room.
Broader Impact and Industry Implications
Beske’s appointment is more than a simple executive hire; it is a signal to the market that Getinge is doubling down on its commitment to its core business. The MedTech sector is currently witnessing a trend where companies are moving away from being generalists to becoming specialists in high-acuity care. By bringing in a leader with specific expertise in image-guided therapy and cardiovascular systems, Getinge is reinforcing its identity as a specialist in life-saving interventions.
Industry analysts suggest that if Beske can successfully navigate the FDA’s requirements and stabilize the production of the Cardiosave and Cardiohelp lines, Getinge could see a significant rebound in its stock valuation and market sentiment. Conversely, if the quality issues persist, the company may face more drastic regulatory actions, including potential consent decrees that could limit its ability to market new products in the United States.
Furthermore, the transition of Elin Frostehav to Vitrolife Group reflects a growing trend of "cross-pollination" in the Swedish MedTech hub of Gothenburg. Both companies are major employers in the region, and the movement of executives between these firms helps foster a robust local ecosystem of innovation and leadership.
Conclusion: A New Chapter for Getinge
As Stacy Beske prepares to take her seat at Getinge’s headquarters in Gothenburg this December, the expectations are high. She inherits a division that is both the company’s greatest asset and its most significant liability. Her mandate is clear: restore the "gold standard" status of Getinge’s acute care products, satisfy the stringent demands of global regulators, and return the division to a path of sustainable, high-margin growth.
With her extensive background at Medtronic and Philips, Beske possesses the unique combination of clinical knowledge and executive grit required for this task. The medical community and investors alike will be watching closely as she begins her tenure, looking for signs that Getinge can move past its recent hurdles and continue its mission of providing life-saving technology to the world’s most vulnerable patients. The success of her leadership will likely determine the trajectory of Getinge for the remainder of the decade.
